BOSTON, MA, July 21, 2015 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today launched the next generation of its Perceptive MyTrials® platform with advanced analytics capabilities. With the Perceptive MyTrials Analytics solution, clinical trial sponsors can now use a mobile-enabled, single entry-point to access predictive data analytics for multiple studies simultaneously. The solution offers real-time and aggregated analytics allowing sponsors and PAREXEL® clinical research professionals to detect key signals and trends. The Perceptive MyTrials Analytics solution also offers cross-sponsor viewing options for clients who need to evaluate data from multiple sponsors.
“As clinical studies become more complex, there is a growing need for real-time and standardized data and analytics from multiple studies,” said Xavier Flinois, President, PAREXEL Informatics. “Using the enhanced tools available with the Perceptive MyTrials Analytics solution, our clients can visualize trends across studies, garner reliable intelligence, and confidently make data-driven business decisions. This information will ultimately help reduce risk, increase clinical trial efficiency, and speed time to market for our clients and for patients.”
Developed by PAREXEL Informatics, the Perceptive MyTrials® platform provides an integrated suite of applications for managing clinical trials. Perceptive MyTrials Analytics offers enhanced analytics capabilities and cross-study business intelligence from within the Perceptive MyTrials platform.
Flinois added, “At PAREXEL, our mission is to bring science to the real world by simplifying a client’s journey at every step. Perceptive MyTrials Analytics is another example of the integrated solutions we are developing that incorporate optimized study management processes that leverage mobile and analytics as part of our broader ‘SMAC’ [social media, mobile, analytics, and cloud] technology approach.”
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.